Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “buy” rating reaffirmed by Wedbush in a report released on Monday, TipRanks reports. They currently have a $140.00 target price on the biopharmaceutical company’s stock. Wedbush’s price target would suggest a potential upside of 192.21% from the company’s previous close.

Several other research analysts have also commented on the company. BMO Capital Markets lowered Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $107.00 to $52.00 in a report on Monday. Goldman Sachs Group lowered Intercept Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $150.00 to $60.00 in a report on Monday. Cowen lowered Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $149.00 to $47.00 in a report on Monday. Royal Bank of Canada lowered Intercept Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $117.00 to $55.00 in a report on Monday. Finally, Oppenheimer lowered Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $124.00 to $46.00 in a report on Monday. Eighteen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $81.48.

Shares of ICPT opened at $47.91 on Monday. Intercept Pharmaceuticals has a 52-week low of $44.50 and a 52-week high of $125.00. The company has a quick ratio of 4.19, a current ratio of 4.19 and a debt-to-equity ratio of 10.32. The firm’s fifty day moving average is $78.84 and its two-hundred day moving average is $88.09. The stock has a market cap of $2.55 billion, a PE ratio of -4.47 and a beta of 1.82.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported ($2.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.94) by $0.08. Intercept Pharmaceuticals had a negative net margin of 127.53% and a negative return on equity of 430.51%. The company had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $69.67 million. During the same quarter in the previous year, the company posted ($3.03) EPS. The firm’s quarterly revenue was up 39.1% on a year-over-year basis. As a group, research analysts anticipate that Intercept Pharmaceuticals will post -11.3 earnings per share for the current year.

In other Intercept Pharmaceuticals news, Director Paolo Fundaro sold 595,578 shares of Intercept Pharmaceuticals stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $84.60, for a total value of $50,385,898.80. Following the completion of the transaction, the director now directly owns 19,433 shares of the company’s stock, valued at approximately $1,644,031.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 595,817 shares of company stock valued at $50,405,516. 23.70% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ICPT. Efficient Wealth Management LLC acquired a new position in Intercept Pharmaceuticals in the 1st quarter valued at about $31,000. PNC Financial Services Group Inc. grew its position in Intercept Pharmaceuticals by 42.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 790 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 234 shares in the last quarter. First Mercantile Trust Co. grew its position in Intercept Pharmaceuticals by 17.5% in the 1st quarter. First Mercantile Trust Co. now owns 938 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 140 shares in the last quarter. Credit Agricole S A acquired a new position in Intercept Pharmaceuticals in the 1st quarter valued at about $76,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Intercept Pharmaceuticals by 17.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,080 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 312 shares in the last quarter. 76.46% of the stock is owned by institutional investors.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Article: What is Net Asset Value (NAV)?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.